Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
IOV-COM-202
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT03645928 ↗
- Terminated
- Iovance Biotherapeutics, Inc.
- Focused
We haven't built an HCP commentary report on IOV-COM-202 (lifileucel, LN-145 and 10 more in Metastatic Melanoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IOV-COM-202 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Metastatic Melanoma; Squamous Cell Carcinoma of the Head and Neck; Non-small Cell Lung Cancer
- Interventions
- Lifileucel; LN-145; Pembrolizumab; LN-145-S1; Ipilimumab; Nivolumab; Nivolumab-relatlimab; Cisplatin; Carboplatin; Paclitaxel; Nab paclitaxel; Pemetrexed
- Arms
- Cohort 1A · Experimental
- Cohort 1B · Experimental
- Cohort 1C · Experimental
- Cohort 2A · Experimental
- Cohort 3A · Experimental
- Cohort 3B · Experimental
- Cohort 3C · Experimental
- Cohort 3D · Experimental
- Cohort 3E · Experimental
- Cohort 1D · Experimental
- Enrollment
- 225
- Primary outcomes
- Objective Response Rate
- Safety Profile Measured by Grade ≥3 TEAEs
- Percentage of patients for whom lifileucel is successfully manufactured and meets release specification
- Sponsor
- Iovance Biotherapeutics, Inc.
- Start
- May 7, 2019
- Primary completion
- Feb 20, 2026
- Results posted
- No
- Registry record
- NCT03645928 · updated May 15, 2026
Publications
linked from the registry- Hensel J, Metts J, Gupta A, Ladle BH, Pilon-Thomas S, Mullinax J. Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy. Cancer J. 2022 Jul-Aug 01;28(4):322-327. doi: 10.1097/PPO.0000000000000603. PubMed 35880942